This notion is further supported by evidence demonstrating that β-blocker therapy in patients with dilated cardiomyopathy (DCM) can partially reverse this maladaptive transcriptional pattern by upregulating MYH6 and downregulating MYH7, an adjustment associated with improved left ventricular ejection fraction [11,12]. The gene discussed is MYH6; the disease is dilated cardiomyopathy.